PT  - JOURNAL ARTICLE
AU  - Okoye, Jude Ogechukwu
AU  - Ado-Okoye, Tochukwu Juliet
AU  - Emeka, Chiemeka Michael
AU  - Eleje, George Uchenna
AU  - Uduchi, Immaculata Ogochukwu
AU  - Okoye, Uchechukwu Lilian
TI  - Immuno-inflammatory-related vulnerabilities and high mortality risk among patients with aggressive early-onset epithelial ovarian cancers in West Africa: A retrospective study
AID  - 10.1101/2023.07.31.23293423
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.31.23293423
4099  - http://medrxiv.org/content/early/2023/08/05/2023.07.31.23293423.short
4100  - http://medrxiv.org/content/early/2023/08/05/2023.07.31.23293423.full
AB  - Introduction This study evaluated systemic immune-inflammatory indices (SIII) among patients with epithelial ovarian cancer (EOC) to identify affordable markers for disease assessment and treatment monitoring. This study did not assess the rate of BRCA2 mutation and SIII in early-onset (≤ 50 years old) and late-onset (> 50 years old) EOC but also evaluated SIII in treatment outcomes.Methods This study included 100 patients diagnosed with EOC from Jan. 2016 to Dec. 2021. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelets-neutrophils-to-lymphocytes ratio (PNLR), and neutrophils-to-lymphocytes platelets ratio (NLPR) were assessed and analyzed accordingly. Significance was set at p< 0.05.Result The frequency of early menarche, serous adenocarcinoma, and late-stage disease was 3.3, 1.6, and 1.4 times higher among patients with early-onset EOC compared with their late-onset counterparts (p= 0.001, 0.025, and 0.397, respectively). The frequency of BRCA2 mutation, hypertension, and diabetes was 2.5, 2.5, and 5.7 times higher among the latter than among the former (p= 0.001, 0.006, and 0.064, respectively). The pre-/post-treatment NLR and PNLR were 2.2/2.4 and 1.7/2.3 times higher among patients who died in the hospital than patients who were stable on discharge, respectively (p< 0.05). Although the pre-chemotherapy PNLR was 2.1 times higher among patients with stages I/II EOC compared with patients with stages III/IV EOC (p= 0.031), there was a 2.5 times significant decline and 1.1 times insignificant decline in pre-to-post-chemotherapy PNLR among the former and latter (p= 0.003 and 0.433, respectively). The post-treatment PNLR, PLR, and TWBC of herbal medicine-experienced patients were 5.6, 1.6, and 1.5, higher than the post-treatment values of naïve counterparts, respectively (p< 0.05).Conclusion This study revealed a high frequency of late-onset EOC but poor chemotherapy response among patients with aggressive early-onset. It suggests that NLR, PNLR, and PLR could be used to monitor disease progression and treatment outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee/IRB of Nnamdi Azikiwe University Teaching Hospital Nnewi gave ethical approval for this work I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript